Juno Therapeutics (NASDAQ:JUNO) is one hot biotechnology stock to watch

0
195
juno therapeutics logo

juno therapeutics logoJuno Therapeutics (NASDAQ:JUNO) is around a year old and it is already worth $5.5 billion. A lot of analysts are beginning to look at this company because of its “CAR-T” genetic engineering technology. This very promising anti-cancer technology wipes out cancer cells by re-engineering the human body’s existing immune cells. In other words, Juno therapy works by collaborating with the body’s own immune system. It may be a year old company, but its technology is not new. Its re-engineering processes is actually based on a compiled research at Fred Hutchinson Cancer Research and Memorial Sloan-Kettering.

The stock has a 52-week low of 34 Dollars and 71 Cents, and has a 52-week high of 62 Dollars and 50 Cents. Considering the amount of buzz there is regarding this company, I would not be surprised if it spikes to higher than 65 Dollars. It is red hot.

The interesting thing about its technology is that, in small scale clinical trials, it has shown that its CAR-T Therapy has produced patient remissions at a rate of 80-90%. The numbers are there and definitely has a lot of buzz. A lot of analysts are beginning to pay attention to this company. But of course, just like any other hot biotech stock, you need to proceed with caution.

Juno’s recent good fortunes does shine a light on other biotech companies which create compounds or chemicals that enable anti-cancer or therapeutic compounds to work with the human body to treat certain conditions. Juno doesn’t have a monopoly on such technology.

LEAVE A REPLY

Please enter your comment!
Please enter your name here